Chronic and acute adenosine A2A receptor blockade prevents long-term episodic memory disruption caused by acute cannabinoid CB1 receptor activation

Francisco M. Mouro, Vânia L. Batalha, Diana G. Ferreira, Joana E. Coelho, Younis Baqi, Christa E. Müller, Luísa V. Lopes, Joaquim A. Ribeiro, Ana M. Sebastião

Research output: Contribution to journalArticle

  • 6 Citations

Abstract

Cannabinoid-mediated memory impairment is a concern in cannabinoid-based therapies. Caffeine exacerbates cannabinoid CB1 receptor (CB1R)-induced memory deficits through an adenosine A1 receptor-mediated mechanism. We now evaluated how chronic or acute blockade of adenosine A2A receptors (A2ARs) affects long-term episodic memory deficits induced by a single injection of a selective CB1R agonist. Long-term episodic memory was assessed by the novel object recognition (NOR) test. Mice received an intraperitoneal (i.p.) injection of the CB1/CB2 receptor agonist WIN 55,212-2 (1 mg/kg) immediately after the NOR training, being tested for novelty recognition 24 h later. Anxiety levels were assessed by the Elevated Plus Maze test, immediately after the NOR. Mice were also tested for exploratory behaviour at the Open Field. For chronic A2AR blockade, KW-6002 (istradefylline) (3 mg/kg/day) was administered orally for 30 days; acute blockade of A2ARs was assessed by i.p. injection of SCH 58261 (1 mg/kg) administered either together with WIN 55,212-2 or only 30 min before the NOR test phase. The involvement of CB1Rs was assessed by using the CB1R antagonist, AM251 (3 mg/kg, i.p.). WIN 55,212-2 caused a disruption in NOR, an action absent in mice also receiving AM251, KW-6002 or SCH 58261 during the encoding/consolidation phase; SCH 58251 was ineffective if present during retrieval only. No effects were detected in the Elevated Plus maze or Open Field Test. The finding that CB1R-mediated memory disruption is prevented by antagonism of adenosine A2ARs, highlights a possibility to prevent cognitive side effects when therapeutic application of CB1R drugs is desired.

LanguageEnglish
Pages316-327
Number of pages12
JournalNeuropharmacology
Volume117
DOIs
Publication statusPublished - May 1 2017

Fingerprint

Adenosine A2A Receptors
Cannabinoid Receptor CB1
Episodic Memory
Long-Term Memory
Cannabinoids
Memory Disorders
Intraperitoneal Injections
Cannabinoid Receptor CB2
Adenosine A1 Receptors
Exploratory Behavior
Therapeutic Uses
Caffeine
Recognition (Psychology)
Anxiety
Injections
Pharmaceutical Preparations
istradefylline
Win 55212-2

Keywords

  • Adenosine A receptor
  • Caffeine
  • Cannabinoid receptor 1
  • Istradefylline
  • Memory
  • Novel object recognition

ASJC Scopus subject areas

  • Pharmacology
  • Cellular and Molecular Neuroscience

Cite this

Chronic and acute adenosine A2A receptor blockade prevents long-term episodic memory disruption caused by acute cannabinoid CB1 receptor activation. / Mouro, Francisco M.; Batalha, Vânia L.; Ferreira, Diana G.; Coelho, Joana E.; Baqi, Younis; Müller, Christa E.; Lopes, Luísa V.; Ribeiro, Joaquim A.; Sebastião, Ana M.

In: Neuropharmacology, Vol. 117, 01.05.2017, p. 316-327.

Research output: Contribution to journalArticle

Mouro, Francisco M. ; Batalha, Vânia L. ; Ferreira, Diana G. ; Coelho, Joana E. ; Baqi, Younis ; Müller, Christa E. ; Lopes, Luísa V. ; Ribeiro, Joaquim A. ; Sebastião, Ana M. / Chronic and acute adenosine A2A receptor blockade prevents long-term episodic memory disruption caused by acute cannabinoid CB1 receptor activation. In: Neuropharmacology. 2017 ; Vol. 117. pp. 316-327.
@article{58e4ad76c3b34451b64b074d659e0a92,
title = "Chronic and acute adenosine A2A receptor blockade prevents long-term episodic memory disruption caused by acute cannabinoid CB1 receptor activation",
abstract = "Cannabinoid-mediated memory impairment is a concern in cannabinoid-based therapies. Caffeine exacerbates cannabinoid CB1 receptor (CB1R)-induced memory deficits through an adenosine A1 receptor-mediated mechanism. We now evaluated how chronic or acute blockade of adenosine A2A receptors (A2ARs) affects long-term episodic memory deficits induced by a single injection of a selective CB1R agonist. Long-term episodic memory was assessed by the novel object recognition (NOR) test. Mice received an intraperitoneal (i.p.) injection of the CB1/CB2 receptor agonist WIN 55,212-2 (1 mg/kg) immediately after the NOR training, being tested for novelty recognition 24 h later. Anxiety levels were assessed by the Elevated Plus Maze test, immediately after the NOR. Mice were also tested for exploratory behaviour at the Open Field. For chronic A2AR blockade, KW-6002 (istradefylline) (3 mg/kg/day) was administered orally for 30 days; acute blockade of A2ARs was assessed by i.p. injection of SCH 58261 (1 mg/kg) administered either together with WIN 55,212-2 or only 30 min before the NOR test phase. The involvement of CB1Rs was assessed by using the CB1R antagonist, AM251 (3 mg/kg, i.p.). WIN 55,212-2 caused a disruption in NOR, an action absent in mice also receiving AM251, KW-6002 or SCH 58261 during the encoding/consolidation phase; SCH 58251 was ineffective if present during retrieval only. No effects were detected in the Elevated Plus maze or Open Field Test. The finding that CB1R-mediated memory disruption is prevented by antagonism of adenosine A2ARs, highlights a possibility to prevent cognitive side effects when therapeutic application of CB1R drugs is desired.",
keywords = "Adenosine A receptor, Caffeine, Cannabinoid receptor 1, Istradefylline, Memory, Novel object recognition",
author = "Mouro, {Francisco M.} and Batalha, {V{\^a}nia L.} and Ferreira, {Diana G.} and Coelho, {Joana E.} and Younis Baqi and M{\"u}ller, {Christa E.} and Lopes, {Lu{\'i}sa V.} and Ribeiro, {Joaquim A.} and Sebasti{\~a}o, {Ana M.}",
year = "2017",
month = "5",
day = "1",
doi = "10.1016/j.neuropharm.2017.02.021",
language = "English",
volume = "117",
pages = "316--327",
journal = "Neuropharmacology",
issn = "0028-3908",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Chronic and acute adenosine A2A receptor blockade prevents long-term episodic memory disruption caused by acute cannabinoid CB1 receptor activation

AU - Mouro, Francisco M.

AU - Batalha, Vânia L.

AU - Ferreira, Diana G.

AU - Coelho, Joana E.

AU - Baqi, Younis

AU - Müller, Christa E.

AU - Lopes, Luísa V.

AU - Ribeiro, Joaquim A.

AU - Sebastião, Ana M.

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Cannabinoid-mediated memory impairment is a concern in cannabinoid-based therapies. Caffeine exacerbates cannabinoid CB1 receptor (CB1R)-induced memory deficits through an adenosine A1 receptor-mediated mechanism. We now evaluated how chronic or acute blockade of adenosine A2A receptors (A2ARs) affects long-term episodic memory deficits induced by a single injection of a selective CB1R agonist. Long-term episodic memory was assessed by the novel object recognition (NOR) test. Mice received an intraperitoneal (i.p.) injection of the CB1/CB2 receptor agonist WIN 55,212-2 (1 mg/kg) immediately after the NOR training, being tested for novelty recognition 24 h later. Anxiety levels were assessed by the Elevated Plus Maze test, immediately after the NOR. Mice were also tested for exploratory behaviour at the Open Field. For chronic A2AR blockade, KW-6002 (istradefylline) (3 mg/kg/day) was administered orally for 30 days; acute blockade of A2ARs was assessed by i.p. injection of SCH 58261 (1 mg/kg) administered either together with WIN 55,212-2 or only 30 min before the NOR test phase. The involvement of CB1Rs was assessed by using the CB1R antagonist, AM251 (3 mg/kg, i.p.). WIN 55,212-2 caused a disruption in NOR, an action absent in mice also receiving AM251, KW-6002 or SCH 58261 during the encoding/consolidation phase; SCH 58251 was ineffective if present during retrieval only. No effects were detected in the Elevated Plus maze or Open Field Test. The finding that CB1R-mediated memory disruption is prevented by antagonism of adenosine A2ARs, highlights a possibility to prevent cognitive side effects when therapeutic application of CB1R drugs is desired.

AB - Cannabinoid-mediated memory impairment is a concern in cannabinoid-based therapies. Caffeine exacerbates cannabinoid CB1 receptor (CB1R)-induced memory deficits through an adenosine A1 receptor-mediated mechanism. We now evaluated how chronic or acute blockade of adenosine A2A receptors (A2ARs) affects long-term episodic memory deficits induced by a single injection of a selective CB1R agonist. Long-term episodic memory was assessed by the novel object recognition (NOR) test. Mice received an intraperitoneal (i.p.) injection of the CB1/CB2 receptor agonist WIN 55,212-2 (1 mg/kg) immediately after the NOR training, being tested for novelty recognition 24 h later. Anxiety levels were assessed by the Elevated Plus Maze test, immediately after the NOR. Mice were also tested for exploratory behaviour at the Open Field. For chronic A2AR blockade, KW-6002 (istradefylline) (3 mg/kg/day) was administered orally for 30 days; acute blockade of A2ARs was assessed by i.p. injection of SCH 58261 (1 mg/kg) administered either together with WIN 55,212-2 or only 30 min before the NOR test phase. The involvement of CB1Rs was assessed by using the CB1R antagonist, AM251 (3 mg/kg, i.p.). WIN 55,212-2 caused a disruption in NOR, an action absent in mice also receiving AM251, KW-6002 or SCH 58261 during the encoding/consolidation phase; SCH 58251 was ineffective if present during retrieval only. No effects were detected in the Elevated Plus maze or Open Field Test. The finding that CB1R-mediated memory disruption is prevented by antagonism of adenosine A2ARs, highlights a possibility to prevent cognitive side effects when therapeutic application of CB1R drugs is desired.

KW - Adenosine A receptor

KW - Caffeine

KW - Cannabinoid receptor 1

KW - Istradefylline

KW - Memory

KW - Novel object recognition

UR - http://www.scopus.com/inward/record.url?scp=85013923719&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85013923719&partnerID=8YFLogxK

U2 - 10.1016/j.neuropharm.2017.02.021

DO - 10.1016/j.neuropharm.2017.02.021

M3 - Article

VL - 117

SP - 316

EP - 327

JO - Neuropharmacology

T2 - Neuropharmacology

JF - Neuropharmacology

SN - 0028-3908

ER -